TGR-1202 hydrochloride
CAS No. 1532533-78-0
TGR-1202 hydrochloride ( RP5264 hydrochloride | TGR1202 hydrochloride | TGR 1202 hydrochloride )
产品货号. M12156 CAS No. 1532533-78-0
TGR-1202 (RP5264,TGR1202,Umbralisib) 是一种有效的、选择性的、口服的 PI3Kδ 抑制剂,IC50 为 22 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥515 | 有现货 |
|
| 5MG | ¥867 | 有现货 |
|
| 10MG | ¥1720 | 有现货 |
|
| 100MG | ¥7407 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥1378 | 有现货 |
|
生物学信息
-
产品名称TGR-1202 hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述TGR-1202 (RP5264,TGR1202,Umbralisib) 是一种有效的、选择性的、口服的 PI3Kδ 抑制剂,IC50 为 22 nM。
-
产品描述TGR-1202 (RP5264,TGR1202,Umbralisib) is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM, 50-fold selectivity over PI3Kα/β and >10,000 fold over PI3Kγ; enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest, demonstrates highly synergistic effect with the proteasome inhibitor carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary lymphoma and leukemia cells; synergistically disrupts the 4E-BP1-eIF4F-c-Myc axis with carfilzomib, also potently inhibits 60% of the activity of CK1ε at 1uM.Blood Cancer Phase 3 Clinical
-
体外实验Umbralisib hydrochloride causes a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM.Umbralisib hydrochloride (10 nM-100 μM) inhibits phosphorylated AKT at Ser473 in a concentration-dependent manner in human lymphoma and leukemia cell lines. Umbralisib hydrochloride (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells.
-
体内实验Umbralisib hydrochloride (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25 in a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line.
-
同义词RP5264 hydrochloride | TGR1202 hydrochloride | TGR 1202 hydrochloride
-
通路PI3K/Akt/mTOR signaling
-
靶点PI3K
-
受体PI3K
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1532533-78-0
-
分子量608.0101
-
分子式C31H25ClF3N5O3
-
纯度>98% (HPLC)
-
溶解度DMSO
-
SMILESCC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F.Cl
-
化学全称4H-1-Benzopyran-4-one, 2-[(1S)-1-[4-amino-3-[3-fluoro-4-(1-methylethoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)-, hydrochloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Locatelli SL, et al. Leukemia. 2016 Dec;30(12):2402-2405.
2. Deng C, et al. Blood. 2017 Jan 5;129(1):88-99.
3. Burris HA 3rd, et al. Lancet Oncol. 2018 Feb 20. pii: S1470-2045(18)30082-2.
4. Lampson BL, et al. Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279.
产品手册
关联产品
-
Wortmannin
一种有效的 PI3K 抑制剂,IC50 为 3 nM,不会抑制 PI4K 活性。
-
ETP-46321
ETP-46321 是一种有效的、选择性的、口服生物可利用的双重 PI3K α/δ 抑制剂,IC50 为 2.3/14.2 nM。
-
Voxtalisib
一种有效的、高选择性的 I 类 PI3K ATP 竞争性抑制剂。
021-51111890
购物车()
sales@molnova.cn

